Rainier Therapeutics (formerly BioClin Therapeutics) is a biotechnology company developing targeted therapy for bladder cancer. Its lead program is Vofatamab, a human monoclonal antibody that targets and blocks the activity of FGFR3 (fibroblast growth factor receptor 3).